Systemic Immun Inflamation Score Corelation in Postoperative Patients Prognosis
150 participantsStarted 2026-06-15
Plain-language summary
The Systemic Immuno-Inflammation Index (SII) is a ratio derived from complete blood count parameters (neutrophils, lymphocytes, platelets) and is a non-invasive and easily calculable biomarker. The SIPI effectively reflects both local and systemic inflammatory responses in the human body. It has been used to predict and evaluate the prognosis of various solid tumors such as gastric cancer, non-small cell lung cancer, and colorectal cancer. Furthermore, the SIPI has been shown to have significant prognostic value in cardiovascular and cerebrovascular diseases. In this study, the SIPI will be calculated using laboratory data at the time of admission to the intensive care unit, and the relationship between the obtained values and the 30-day mortality status of the patients will be analyzed.
Who can participate
Age range
65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* The patient must be 65 years of age or older (in the geriatric age group),
* Admitted to the intensive care unit after elective or emergency surgery
* Have access to complete blood count (hemogram) data (neutrophils, lymphocytes, platelets) during their stay in the intensive care unit
* Be able to undergo 30-day mortality monitoring from the date of admission to the intensive care unit
* Have provided informed consent from the patient or their legal representative.
Exclusion Criteria:
* Patients under 65 years of age
* Patients admitted to the intensive care unit for non-surgical reasons (e.g., trauma, medical intensive care indications)
* Patients with deficient neutrophil, lymphocyte, or platelet counts upon admission to the intensive care unit
* Patients with a history of malignancy, hematological disease, or immunosuppressive therapy
* Terminally ill palliative patients
* Patients who refuse informed consent.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Measuring the Systemic Immune-Inflammation Index (SII) in postoperative patients to see the parameter's predictibility of 30-day mortality